Esophageal Cancer
Conditions
Keywords
adenocarcinoma of the esophagus, squamous cell carcinoma of the esophagus, stage II esophageal cancer, stage III esophageal cancer
Brief summary
RATIONALE: Drugs used in chemotherapy such as paclitaxel, fluorouracil, and cisplatin use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining chemotherapy with radiation therapy may kill more tumor cells PURPOSE: This phase II trial is studying how well combination chemotherapy followed by chemoradiotherapy, with or without surgery, works in treating patients with resectable locally advanced cancer of the esophagus or gastroesophageal junction.
Detailed description
OBJECTIVES: * Determine the feasibility of treatment with paclitaxel, cisplatin, and fluorouracil followed by chemoradiotherapy and possible surgical salvage in patients with resectable locally advanced carcinoma of the esophagus or gastroesophageal junction. * Determine the overall and disease-free survival of patients treated with this regimen. * Determine the treatment-related toxicity of this regimen in these patients. * Determine the tolerance to surgical salvage in patients treated with this regimen. * Determine the morbidity and mortality of surgical salvage in patients treated with this regimen. OUTLINE: This is a multicenter study. * Induction therapy: Patients receive fluorouracil (5-FU) IV continuously over 96 hours beginning on days 1 and 29; cisplatin IV over 1 hour on days 1-5 and 29-33; paclitaxel IV over 2 hours on days 1 and 29; and pegfilgrastim subcutaneously (SC) on days 6 and 34 OR filgrastim (G-CSF) SC on days 6-15 and 34-42. Treatment continues in the absence of unacceptable toxicity. * Chemoradiotherapy: Patients receive cisplatin IV over 1 hour on days 57-61 and 5-FU IV continuously on days 57-61, 64-68, 71-75, 78-82, 85-89, and 92-96. Patients concurrently undergo external beam radiotherapy on days 57-61, 64-68, 71-75, 78-82, 85-89, and 92-96. Patients with residual or recurrent esophageal disease 4-6 weeks after completion of chemoradiotherapy may undergo salvage esophagectomy. Patients are followed periodically. PROJECTED ACCRUAL: A total of 42 patients will be accrued for this study within 18 months.
Interventions
BIOLOGICALfilgrastim
During induction therapy, patients ≤ 70 kg will receive 300 μg OR patients \>70 kg will receive 480 μg subcutaneously on days 6-15 and 34-42.
BIOLOGICALpegfilgrastim
During induction therapy, patients receive 6 mg subcutaneously on days 6 and 34.
DRUGcisplatin
During induction therapy, patients receive 15 mg/m\^2/day by IV over 1 hour on days 1-5 and 29-33. During radiotherapy, patients receive 15 mg/m\^2/day by IV over 1 hour beginning on days 57-61.
DRUGfluorouracil
During induction therapy, patients receive 650 mg/m\^2/day by IV continuously over 96 hours beginning on days 1 and 29. During radiotherapy, patients receive 300 mg/m\^2/day by IV continuously over 96 hours beginning on day 57 for 5 cycles.
DRUGpaclitaxel
During induction therapy, patients receive 200 mg/m\^2/day by IV over 2 hours on days 1 and 29.
PROCEDUREconventional surgery
Patients with residual or recurrent esophageal disease 4-6 weeks after completion of chemoradiotherapy may undergo salvage esophagectomy.
RADIATIONradiation therapy
External beam radiotherapy with megavoltage linear accelerators (\> 6 MV) will be used to deliver multiple (\> 2) field techniques. Patients will be treated 5 days/week at 1.8 Gy/day for 28 days for a total dose of 50.4 Gy.
Sponsors
National Cancer Institute (NCI)
NRG Oncology
Radiation Therapy Oncology Group
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 120 Years
Healthy volunteers
No
Inclusion criteria
DISEASE CHARACTERISTICS: * Histologically confirmed squamous cell carcinoma or adenocarcinoma of the esophagus or gastroesophageal junction * Primary (non-recurrent) disease * Amenable to resection * Stage greater than T1, N0 by endoscopic ultrasound * Must be entirely confined to the esophagus or gastroesophageal junction and periesophageal soft tissue * Tumor may not extend more than 2 cm into the stomach * No multiple primary carcinomas of the esophagus * No cervical esophageal carcinoma or tumors less than 5 cm from cricopharyngeus * No evidence of disseminated cancer * Suggestion of liver metastases by positron emission tomography must be proven negative by biopsy or other imaging studies * Palpable supraclavicular nodes must be negative for cancer by biopsy * Bronchoscopy required for lesions less than 26 cm from the incisors to exclude tracheoesophageal fistula or invasion * No celiac adenopathy greater than 2 cm PATIENT CHARACTERISTICS: Age * 18 and over Performance status * Zubrod 0-1 Life expectancy * Not specified Hematopoietic * Absolute granulocyte count at least 1,500/mm\^3 * Platelet count at least 150,000/mm\^3 * Hemoglobin at least 10 g/dL Hepatic * Not specified Renal * Creatinine no greater than 1.5 mg/dL AND/OR * Creatinine clearance at least 65 mL/min * Calcium no greater than 11 mg/dL Cardiovascular * No uncontrolled heart disease * No uncontrolled hypertension Other * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * Able to comprehend study requirements and considered likely to comply with study parameters * No other malignancy within the past 5 years except curable nonmelanoma skin cancer or carcinoma in situ of the cervix * No uncontrolled diabetes * No hypersensitivity to E. coli-derived products PRIOR CONCURRENT THERAPY: Biologic therapy * Not specified Chemotherapy * More than 5 years since prior systemic chemotherapy Endocrine therapy * Not specified Radiotherapy * No prior chest or upper abdomen radiotherapy Surgery * No prior esophageal or gastric surgery Other * No concurrent photodynamic therapy * No other concurrent investigational agents for esophageal carcinoma
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall Survival (1-year Rate Reported) | From registration to date of death or last follow-up. Analysis occurs after all patients have been potentially followed for 1 year. | One-year survival estimate is reported. Survival time is defined as time from registration to date of death from any cause and is estimated by the Kaplan-Meier method. Patients last known to be alive are censored at date of last contact. This analysis was planned to occur when all patients had been potentially followed for 1 year. On the basis of a 1-year survival rate of 60% from the Radiation Therapy Oncology Group (RTOG) esophageal database, 38 analyzable patients with a 1-year survival rate of 77.5% or better was needed for this trial to be deemed promising enough for development of a Phase III protocol (type I error of 0.05 and type II error of 0.20). |
Secondary
| Measure | Time frame |
|---|---|
| Frequency of Major (Grade 4) Acute Treatment-related Toxicities | From start of chemotherapy to surgery or 2 months after chemoradiation (for patients not undergoing surgery). |
| Frequency of Patients With Persistent or Recurrent Disease Eligible for Surgical Salvage Resection | Analysis occurs with the primary outcome measure. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| ChemoRT and Selective Surgery Induction therapy of fluorouracil, cisplatin, paclitaxel, and pegfilgrastim OR filgrastim, then chemoradiotherapy of concurrent cisplatin and fluorouracil with external beam radiotherapy (RT), followed by selective salvage therapy. | 41 |
| Total | 41 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| Overall Study | Protocol Violation | 2 |
Baseline characteristics
| Characteristic | ChemoRT and Selective Surgery |
|---|---|
| Age, Continuous | 59 years |
| Gender Female | 7 Participants |
| Gender Male | 34 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | — / — |
| other Total, other adverse events | 41 / 41 |
| serious Total, serious adverse events | 26 / 41 |
Outcome results
Primary
Overall Survival (1-year Rate Reported)
One-year survival estimate is reported. Survival time is defined as time from registration to date of death from any cause and is estimated by the Kaplan-Meier method. Patients last known to be alive are censored at date of last contact. This analysis was planned to occur when all patients had been potentially followed for 1 year. On the basis of a 1-year survival rate of 60% from the Radiation Therapy Oncology Group (RTOG) esophageal database, 38 analyzable patients with a 1-year survival rate of 77.5% or better was needed for this trial to be deemed promising enough for development of a Phase III protocol (type I error of 0.05 and type II error of 0.20).
Time frame: From registration to date of death or last follow-up. Analysis occurs after all patients have been potentially followed for 1 year.
Population: All eligible patients.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| ChemoRT and Selective Surgery | Overall Survival (1-year Rate Reported) | 71 percentage of participants |
Secondary
Frequency of Major (Grade 4) Acute Treatment-related Toxicities
Time frame: From start of chemotherapy to surgery or 2 months after chemoradiation (for patients not undergoing surgery).
Secondary
Frequency of Patients With Persistent or Recurrent Disease Eligible for Surgical Salvage Resection
Time frame: Analysis occurs with the primary outcome measure.